Ali Khademhosseini wins Biomaterials Global Impact Award
Biomaterial, the prestigious international journal covering the science and clinical application of biomaterials announced a Mustafa(pbuh) prize laureate, Ali Khademhosseini as the winner of Biomaterials Global Impact Award for 2024.
MSTF media reports
Ali Khademhosseini, CEO and Founding Director at the Terasaki Institute for Biomedical Innovation and a laureate of the 2019 Mustafa(pbuh) prize in the field of Life & Medical Science and Technology, was the winner of Biomaterials Global Impact Award for 2024.
According to Biomaterial, “He has made seminal contributions to modifying hydrogels and developing novel biomaterial solutions for addressing pressing problems in healthcare. He has founded 3 companies, Obsidio Medical which was recently acquired by Boston Scientific, Omeat and BioRAE.”
“Khademhosseini is an author on >700 peer-reviewed journal articles, and review papers, >70 book chapters/edited books and >50 patents/patent applications. He has been cited >121,800 times and has an H-index of 178,” Biomaterial went on.
He received his Ph.D. in bioengineering from MIT (2005), and MASc (2001) and BASc (1999) degrees from University of Toronto both in chemical engineering.
The Biomaterials Global Impact Award recognizes distinguished research and development accomplishments in the field of biomaterials. This year, Ali Khademhosseini, shared the award with Professor Antonios Mikos of Rice University.
In 2019, he received Mustafa(pbuh) prize for his work “Nano and Micro fabricated Hydrogels for Biomedical Applications”. Nominations are now open for the 2025 Mustafa(pbuh) prize. The deadline for nominations is August 31, 2024.
